erbB2 Overexpression in Uterine Serous Cancer: A Target for Trastuzumab Therapy
Author Information
Author(s): K. S. ElSahwi, A. D. Santin
Primary Institution: Yale University School of Medicine
Hypothesis
Trastuzumab may be an attractive treatment option for advanced stage uterine serous cancer tumors that overexpress erbB2.
Conclusion
The study suggests that trastuzumab could be a viable treatment for advanced stage uterine serous cancer that overexpresses erbB2.
Supporting Evidence
- Trastuzumab has shown activity in vitro and in case reports for advanced and recurrent uterine serous cancer.
- Patients with erbB2 overexpression had worse survival outcomes.
- Trastuzumab treatment led to significant partial responses in some heavily pretreated patients.
Takeaway
This study looks at a medicine called trastuzumab that might help treat a type of uterine cancer that has a special marker called erbB2. It shows promise for helping patients with this cancer.
Methodology
The study involved analyzing erbB2 overexpression in uterine serous cancer specimens and reviewing case reports of trastuzumab treatment.
Limitations
The study's findings are based on case reports and may not be generalizable to all patients with uterine serous cancer.
Participant Demographics
The study notes a higher incidence of erbB2 overexpression in African American women compared to Caucasians.
Statistical Information
P-Value
P = 0.0008
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website